SGLT2 inhibitors associated with lower all-cause mortality in heart transplant recipients with type 2 diabetes
SGLT2 inhibitors associated with lower mortality in heart transplant patients
This meta-analysis examined the impact of SGLT2 inhibitor use on outcomes for heart transplant recipients with type 2 diabetes. The authors …
New analysis suggests SGLT2 inhibitors may lower death rates for heart transplant recipients with type 2 diabetes without increasing UTI ris…
Multi-target therapies may address combined hypertension and dyslipidemia pathophysiology
Multi-Target Therapies May Address Combined Hypertension and High Cholesterol
This systematic review synthesizes evidence on synergistic mechanisms of hypertension and dyslipidemia, highlighting the RAAS/PPAR axis, AMP…
Combining treatments like statins and RAAS inhibitors may offer a more precise way to manage both high blood pressure and cholesterol levels…
SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings
SGLT2 inhibitors show promise for heart failure and diabetes
This narrative review examines the cardiovascular and metabolic effects of SGLT2 inhibitors, specifically empagliflozin and dapagliflozin. T…
New evidence shows how SGLT2 inhibitors may protect the heart and manage risks for patients with type 2 diabetes and heart failure.
Network meta-analysis ranks FGF21 analogs and SGLT2 inhibitors highest for MASH fibrosis
New analysis shows SGLT2 inhibitors may help liver scarring improve in adults with fatty liver disease
A network meta-analysis of 34 trials found FGF21 analogs and SGLT2 inhibitors ranked highest for improving liver fibrosis in MASH, with GLP-…
A large review of trials found SGLT2 inhibitors ranked highest for reducing liver scarring. These drugs also showed good safety and balanced…
Real-time CGM improved HbA1c versus SMBG in adults with type 2 diabetes on basal insulin and modern therapies
Real-time glucose monitoring improves blood sugar control in type 2 diabetes
This randomised controlled trial compared real-time continuous glucose monitoring against standard self-monitoring of blood glucose in adult…
A new trial shows continuous glucose monitoring helps lower blood sugar levels better than standard finger-prick testing for adults with typ…
SGLT2 inhibitor use associated with increased diabetic ketoacidosis risk, especially with elevated HbA1c
New review shows SGLT2 drugs raise DKA risk when blood sugar is high
This meta-analysis of observational and randomized trials found SGLT2 inhibitor use is associated with an increased risk of diabetic ketoaci…
A big review of many studies found that medicines for diabetes called SGLT2 inhibitors can increase the chance of a serious condition called…
Narrative review examines metabolic syndrome and novel agents in kidney transplant recipients
Kidney transplant patients face high metabolic risks and rejection
This narrative review addresses antibody-mediated rejection and metabolic syndrome in kidney transplantation recipients. The authors note th…
About half of kidney transplant recipients develop metabolic problems within a year, while antibody-mediated rejection remains a major cause…
Network meta-analysis of finerenone and SGLT2 inhibitors in heart failure with preserved or mildly reduced ejection fraction
New analysis shows finerenone and SGLT2 drugs help lower heart failure hospitalization risks for patients with preserved ejection fraction
This network meta-analysis evaluated finerenone, sodium–glucose cotransporter 2 inhibitors, renin–angiotensin system inhibitors, and angiote…
A large review of over 65,000 patients found that finerenone and SGLT2 inhibitors reduce hospital stays and worsening heart failure compared…
Meta-analysis finds SGLT2 inhibitors reduce cardiac arrest risk in CKD patients
SGLT2 Inhibitors Lower Cardiac Arrest Risk in Kidney Disease
This meta-analysis of 8 RCTs evaluated SGLT2 inhibitors versus placebo in patients with chronic kidney disease. SGLT2i significantly reduced…
A meta-analysis of 8 trials found SGLT2 inhibitors cut cardiac arrest risk by 47% in chronic kidney disease patients, though other arrhythmi…
Combining finerenone with SGLT2 inhibitors lowers mortality and cardiovascular events in diabetic chronic kidney disease patients
A Two-Drug Combo May Save Lives in Diabetic Kidney Disease
A meta-analysis of 1,580 patients shows dual therapy with finerenone and SGLT2 inhibitors significantly reduces mortality and kidney events …
A new analysis finds that pairing finerenone with an SGLT2 inhibitor may significantly lower the risk of death and heart problems for people…
Network meta-analysis compares bexagliflozin efficacy and safety with other SGLT2 inhibitors in type 2 diabetes
New analysis shows bexagliflozin helps lower blood sugar and weight in adults with type 2 diabetes compared to other drugs
This systematic review and network meta-analysis synthesized evidence on bexagliflozin versus other SGLT2 inhibitors and placebo in adults w…
A large review of 26,838 patients found bexagliflozin lowers blood sugar and weight well. It also lowers blood pressure and causes fewer inf…
Meta-analysis shows SGLT2 inhibitors reduce all-cause mortality in heart failure patients
Heart Drug Cuts Death Risk by 14% in Heart Failure Patients
This meta-analysis evaluated SGLT2 inhibitor therapy in patients with heart failure, irrespective of ejection fraction or diabetes status. T…
A heart failure drug originally made for diabetes now shows it can cut death risk by 14% and keep people out of the hospital, and it works f…
All SGLT2 inhibitors Articles
- SGLT2 inhibitors associated with lower all-cause mortality in heart transplant recipients with type 2 diabetes
- Multi-target therapies may address combined hypertension and dyslipidemia pathophysiology
- SGLT2 inhibitors provide robust prognostic benefits in heart failure with inconsistent results in post-myocardial infarction settings
- Network meta-analysis ranks FGF21 analogs and SGLT2 inhibitors highest for MASH fibrosis
- Real-time CGM improved HbA1c versus SMBG in adults with type 2 diabetes on basal insulin and modern therapies
- SGLT2 inhibitor use associated with increased diabetic ketoacidosis risk, especially with elevated HbA1c
- Narrative review examines metabolic syndrome and novel agents in kidney transplant recipients
- Network meta-analysis of finerenone and SGLT2 inhibitors in heart failure with preserved or mildly reduced ejection fraction
- Meta-analysis finds SGLT2 inhibitors reduce cardiac arrest risk in CKD patients
- Combining finerenone with SGLT2 inhibitors lowers mortality and cardiovascular events in diabetic chronic kidney disease patients
- Network meta-analysis compares bexagliflozin efficacy and safety with other SGLT2 inhibitors in type 2 diabetes
- Meta-analysis shows SGLT2 inhibitors reduce all-cause mortality in heart failure patients
- Meta-analysis and cohort study suggest association between SGLT2 inhibitors and reduced arrhythmia recurrence
- Scoping review finds SGLT2 inhibitors show kidney protection in IgA nephropathy
- Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease
- Computational model review predicts dual optima for combination therapy in ageing
- Meta-analysis of dapagliflozin for renal outcomes in type 2 diabetes and CKD
- Systematic review links hypertension, diabetes, and pulmonary inflammation; SGLT2 inhibitors show potential
- Jordan guideline review highlights SGLT2 inhibitor access barriers for heart failure patients
- Semaglutide linked to lower neuropsychiatric event risk vs other diabetes drugs in observational study
- Meta-analysis of adjunctive SGLT2 inhibitors in type 1 diabetes shows mixed safety and efficacy signals
- Review of new-user target trial emulation comparing semaglutide and SGLT2i in U.S. Veterans with type 2 diabetes
- Narrative review conceptualizes CVD as systemic immune–metabolic–inflammatory disease
- SGLT2i use linked to lower adherence and QOL in HF patients in cross-sectional MTAC study
- Semaglutide dose linked to lower mortality and cardiovascular risk in patients with baseline CVD
- Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes
- FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction
- FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk and Improve Glycemic Control in Adults with Type 2 Diabetes
- Meta-analysis finds SGLT2 inhibitors reduce mortality and hospitalization in older heart failure patients
- Self-management and glycemic control linked to lower MCI risk in rural elderly with type 2 diabetes
- Structured exercise program improves glycemic control and fitness in Bangladeshi adults with type 2 diabetes
- SGLT2 inhibitors associated with lower mortality in ATTR-CM patients receiving disease-modifying therapy
- SGLT2 inhibitors reduce weight and fat mass in older adults with T2DM, with smaller muscle mass decline